Latest Teva Pharmaceuticals News & Updates

See the latest news and media coverage for Teva. We track all announcements, press releases, and industry mentions in real time, all in one place.

Teva Pharmaceuticals (Teva)

Global pharmaceutical company

tevapharm.com

Headquarters: Tel-Aviv, Israel
Company type: Public company
Number of employees: 30,000+

Last updated Today

Latest news about Teva Pharmaceuticals (Teva)

In short: Teva Pharmaceutical achieved several financial growth milestones, secured multiple biosimilar approvals, and pursued a strategy of targeted acquisitions.

Company announcements

May 21 Teva

Teva's EMA application for olanzapine LAI accepted

The long-acting injectable aims to improve adherence and is administered every four weeks.

May 18 Teva

Teva receives Fitch credit rating upgrade to investment grade

Fitch raised Teva's corporate credit rating to BBB- with stable outlook, reflecting strong financial progress.

April 30 Teva

Teva published its 2025 Healthy Future Report highlighting sustainability progress

The company met all sustainability-linked bond targets, reduced GHG emissions by 39%, and expanded patient access to nearly 8 million people through product donations.

April 29 Teva

Teva to acquire Emalex Biosciences for up to $900 million

The deal includes ecopipam, a first-in-class therapy for Tourette syndrome, with NDA submission expected in 2H 2026.

Media coverage

June 2 Seeking Alpha

UroGen settles with Teva over Jelmyto patent dispute

UroGen (URGN) stock and Teva Pharmaceuticals (TEVA) stock are in focus as the companies settle a patent dispute. Read more here.

May 22 GlobeNewswire

The European Medicines Agency Accepts Teva’s Marketing

They combine active pharmaceutical ... or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology...

May 17 AD HOC NEWS

Teva Pharmaceutical stock (US88162G1031): Beats Q1 2026 earnings with CNS growth

Teva Pharmaceutical reported strong Q1 2026 results on April 29, beating EPS expectations at $0.53 versus estimates, driven by CNS portfolio sales up to $837...

May 17 The Globe and Mail

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Never miss news about Teva

Track Teva and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Teva competitors & trending companies

Browse news for competitors to Teva and other trending companies.